murine colonic adenocarcinoma cell line CT26.WT / 实用医学杂志

Objective To explore the antigen presentation of CT26.WT via intra-peritoneal injection. Methods The intra-peritoneal injection model was made via injecting cell suspensions in mice. The spleen was isolated from BALB/c mice toco-culture with CT26.WT to detect tumor-killed ability. Phenotype identification methods and CCK8 massy were used to measure the ability of antigen presentation and stimulate T lymphocyte proliferation. IHC was used to detect the expression of B7H4 in normal and tumor tissues. Results Along with the extension of intra-peritoneal injection, the surviving number of cells was increased, contrary to the apoptosis. DC cells failed in maturation and impaired in stimulating T lymphocyte proliferation. B7H4 was higher in tumor tissues. Conclusions With the extension of intra-peritoneal injection, the mature DC cells were scared in number, resulting in the impairement of antigen-presentation. Moreover, the higher B7H4 expression in tumor tissues led to the lack of second signals which may stimulate T cells. Consequently, the ability of T cells in killing tumor cells was decreased so that they escape immunosurveillance.

Experimental study of antitumor of spleen LAK cell and LAK-88/DC cell (?)ne from 615 Inbred mice / 中国免疫学杂志

In the present experiment, we investigated the im munoprophylactic and immunotherapeutic effects of transferring spleen LAK cells or " LAK-88/DC " cells from 615 inbred mice against mouse leukemia. The results showed that transferring LAK cells or "LAK-88/DC" cells and injecting conditional medium for a week 21 days before L615 inoculation induced significant prophylactic effects, which cured 80% of the L615-sufferring mice. Injecting conditional medium alone was also effective, which cured 60% of the mice, While transferring LAK cells or "LAK-88/DC" cells at the same time with L615 inoculation or 1 day after L615 inoculation presented no apparent therapeutic effect. However, when combined with cyclophosphamide (CY) chemotherapy, the transfer of LAK cells or "LAK-88/DC " cells 5 days after L615 inoculation could prolong the mean survival time and even cured 25%-28.6% of the advanced L615 leukemic mice.